FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to								
Section 16. Form 4 or Form 5								
obligations may continue. See								
Instruction 1(b).								

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HASTINGS PAUL J						2. Issuer Name and Ticker or Trading Symbol PROTEON THERAPEUTICS INC PRTO								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
						101	<u> LOIT</u>		TUIT LO	1100	7 11 10	2 [11(1)	,	X Dire	tor		10% Ow	ner	
(Last) (First) (Middle) C/O PROTEON THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 06/08/2018								Offic belo	er (give title v)		Other (s below)	pecify	
200 WEST STREET						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street) WALTHAM MA 0245			02451		-	Line) X Form filed by										l by One Reporting Person I by More than One Reporting			
(City)	(Si	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						ar) i	A. Deemed Execution Date, f any Month/Day/Year)		Transaction Disposed Code (Instr. 5)			ties Acquired (A) o d Of (D) (Instr. 3, 4 a		Benef Owner	ies cially Following	Form (D) o	n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code V	Am	nount	(A) or (D)	Price	Transa	Reported Transaction(s) (Instr. 3 and 4)		[Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	Code (I			5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ve es d ed nstr.	6. Date Exercisable a Expiration Date (Month/Day/Year)		and	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivativ Security (Instr. 5)		e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expira Date	ation	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$2.5	06/08/2018			A		12,700		(1)	06/07/	//2028	Common Stock	12,700	\$0	12,70	0	D		

Explanation of Responses:

1. The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders.

/s/ George A. Eldridge,

attorney-in-fact for Paul J. 06/11/2018

Hastings

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.